Geneva Statement on Heritable Human Genome Editing: The Need for Course Correction
By Roberto Andorno, Françoise Baylis, Marcy Darnovsky, Donna Dickenson, Hille Haker, Katie Hasson, Leah Lowthorp, et al.,
Trends in Biotechnology
| 01. 31. 2020
Heritable Human Genome Editing: Nearing a Critical Juncture
The impending decision about whether to develop and use heritable human genome modification carries high stakes for our shared future. Deciding to proceed with altering the genes of future children and generations would mean abandoning the restraint urged by the United Nations (UN) General Assembly’s formal endorsement of the Universal Declaration on the Human Genome and Human Rights [1] and required by the laws and regulations of more than 50 nations (F. Baylis et al., in preparation), including 29 that have ratified the Oviedo Convention, a binding international treaty [2]. Policymakers put these prohibitions in place to protect human rights and the fundamental equality of all people; to safeguard the physical, psychological, and social wellbeing of children; and to avert the emergence of a new eugenics.
Despite the persistence of these fundamental and widely shared concerns, a small but vocal group of scientists and bioethicists now endorse moving forward with heritable human genome editingi,ii [3]. They have taken it as their task...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...